Skip to main content
CAMBIUM BIO LIMITED logo

CAMBIUM BIO LIMITED — Investor Relations & Filings

Ticker · CMB ISIN · AU0000327769 ASX Professional, scientific and technical activities
Open in API
Filings indexed 504 across all filing types
Latest filing 2022-07-20 Interim / Quarterly Rep…
Country AU Australia
Listing ASX CMB

About CAMBIUM BIO LIMITED

https://www.cambium.bio

Cambium Bio Limited is a clinical-stage regenerative medicine company focused on developing innovative cellular therapies to treat unmet medical needs in ophthalmology and inflammatory diseases. The company's primary focus is on its lead candidate, EluRegen, a first-in-class topical biologic designed for the treatment of corneal epithelial defects and dry eye disease. Utilizing its proprietary technology platforms, the company aims to harness the regenerative potential of biologics to provide effective treatments for chronic conditions. In addition to its ophthalmic pipeline, the company maintains assets in the field of mesenchymal stem cell therapies, including Progenza, which targets osteoarthritis and neuropathic pain. The company emphasizes a data-driven approach to clinical development, seeking to improve patient outcomes through advanced tissue engineering and cell-based solutions.

Recent filings

Filing Released Lang Actions
Quarterly Activities/Appendix 4C Cash Flow Report 9 pages 352.7KB
Interim / Quarterly Report Classification · 100% confidence The document is an ASX announcement dated 21 July 2022 titled 'Quarterly Cashflow Report & Business Update – Period ending 30 June 2022'. It includes detailed financial data such as cash flow statements, cash balances, payments to related parties, and financing activities for the quarter ending 30 June 2022. The presence of the Appendix 4C quarterly cash flow report, which is a regulatory requirement for entities listed on the ASX, confirms this is a quarterly financial report. The document contains substantive financial data and analysis for a period shorter than a full fiscal year, consistent with an Interim / Quarterly Report. It is not merely an announcement of a report or a certification, but the actual report itself. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q4 2022
2022-07-20 English
Notification of cessation of securities - RGS 4 pages 24.2KB
Regulatory Filings Classification · 95% confidence The document is a notification regarding the cessation of certain securities (options) for the entity REGENEUS LTD. It details the number of securities that have ceased, the reason for cessation, and the updated issued capital following these changes. The document is an announcement about changes in the company's securities, specifically the lapse of options, and does not contain financial statements or detailed financial performance data. It is not a full report but a regulatory announcement about securities status changes. This fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2022-06-29 English
Change of Director's Interest Notice 2 pages 220.3KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including the number of shares disposed and held before and after the change. This is a report of personal share transactions by a company director, which fits the definition of Director's Dealing filings. The document length is 3557 characters, which is consistent with a detailed notice rather than a brief announcement. There is no indication that this is an annual report, audit report, or any other type of filing. Therefore, the correct classification is Director's Dealing (DIRS).
2022-06-16 English
Regeneus CEO cements support 2 pages 133.9KB
Director's Dealing Classification · 100% confidence The document is an ASX announcement dated 10 June 2022, detailing the CEO's purchase of 3.8 million shares. It discusses the CEO's share purchase, the company's financial position, and recent funding secured. There is no financial report, earnings data, or detailed financial statements included. The document is primarily an announcement of a director's personal share transaction. Therefore, it fits the category of Director's Dealing (DIRS). The document length is under 5,000 characters and is a straightforward announcement, not a report or presentation.
2022-06-09 English
Quarterly Activities/Appendix 4C Cash Flow Report 8 pages 361.7KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement dated 29 April 2022, titled 'Quarterly Cashflow Report & Business Update – Period ending 31 March 2022'. It includes detailed financial data such as cash flows from operating, investing, and financing activities, loan facility details, payments to related parties, and estimated cash available for future operations. The presence of the Appendix 4C quarterly cash flow report, which is a regulatory requirement for entities listed on the ASX, confirms this is a quarterly financial report. The document is comprehensive and contains substantive financial data and analysis for the quarter ending 31 March 2022, which fits the definition of an Interim / Quarterly Report (IR). It is not merely an announcement of a report or a certification, but the actual report itself with detailed financial statements and business updates. Therefore, the correct classification is IR with high confidence. Q3 2022
2022-04-28 English
Notification of cessation of securities - RGS 4 pages 24.1KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Notification of cessation of +securities' and details the lapse of certain options (securities) for REGENEUS LTD. It provides specific information about the securities that have ceased, the reason for cessation, and the updated issued capital following these changes. The document is an announcement about changes in the company's securities, specifically the cessation of certain securities, rather than a financial report or detailed analysis. It is not an annual report, earnings release, or management report. It is also not a regulatory filing or certification. The content fits best with announcements related to changes in capital structure or securities status. According to the filing definitions, this corresponds to 'Share Issue/Capital Change' (SHA), which covers announcements regarding new share issues, stock splits, or other capital changes, including cessation of securities.
2022-03-07 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.